Monday, 31 August 2026European Markets

EHC ORD SHARES Stock Was Up By 9.29% Today

Loading stream...

(VIANEWS) - The Market ended the session with EHC ORD SHARES (EHCS.AS) rising 9.29% to €10.00 on Monday while AEX-Index dropped 0.03% to €786.82.

EHC ORD SHARES's last close was €10.00, 4.76% under its 52-week high of €10.50.

About EHC ORD SHARES

European Healthcare Acquisition & Growth Company B.V. does not have significant operations. The company focuses on effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more companies or businesses. It also focuses on acquiring companies or businesses in the healthcare sector with a focus on biotechnology and specialty pharma, pharma services, medical technology and medical devices, diagnostic and lab services, and bioinformatics, as well as life science tools subsectors in Europe. The company was incorporated in 2021 and is based in Munich, Germany.

Earnings Per Share

As for profitability, EHC ORD SHARES has a trailing twelve months EPS of €-0.47.

Yearly Top and Bottom Value

EHC ORD SHARES's stock is valued at €10.00 at 21:30 EST, below its 52-week high of €10.50 and way higher than its 52-week low of €9.00.

Moving Average

EHC ORD SHARES's value is higher than its 50-day moving average of €9.68 and above its 200-day moving average of €9.86.

More news about EHC ORD SHARES (EHCS.AS).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Hawkish Fed Signals at Jackson Hole Pressure Rate-Sensitive Assets
Kevin Warsh's hawkish inflation remarks at Jackson Hole, alongside a steady drumbeat of Federal Reserve testimony from Powell, Barr, Bowman and other officials on supervision, regulation and monetary policy, signal continued vigilance against inflation rather than an imminent easing cycle. Rate-sensitive and precious-metals-linked names such as SSR Mining sold off the same day, consistent with markets repricing for a firmer-for-longer policy stance.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,979
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,979 facts checked against source5,261 source documents archived
Query this data → isubstrate.com